Sean, interesting couple of weeks. I got off my few shares barely in time but didn't realize the $1.50 spike a couple of weeks ago. My prediction doesn't look too hot today.
Somewhere down here IZP is starting to look like a buy again, don't you think?
Last Friday I hosted a luncheon for a number of Pharma types. Dr. Bains from Nortran, Radvak from Response Pharmaceuticals, a couple of (X)IR from Pyng Medical, one of the IR's(Marley-Clarke) from Wolf Industries (Dental Analyzer,WLFN NASDAQ OTC), and the usual suspects from Howe Street.
It was a good bull session(I guess today we call it networking). Of course we talked about the changes down at IZP and tried to guessed the direction of the company and more important(to me anyway) "what was the price potential of the stock and its timing?".
Consensus was "the company need only a little tweaking". That's my layman's description of proving some of the drugs claims scientifically. The learned scientists at the table thought only some peripheral testing on a few remaining items would be sufficient to demonstrate the efficacy and safety the drug and the diligence of the testing to date.(My apology to the Doctors on the thread for my crude explanation. The last paragraph is what happens when two worlds collide!)
We also talked about the likely hood of selling to a major, in what ever form. Consensus, "absolutely". When, "probable when the tweaking is done".
What is the value of the company, post tweaking, "$80m to 100m".
What is a realistic price of the stock, I am not sure of the outstanding shares, I think in the neighborhood of 30m. Stock price "$3.00 to $4.00". "Hopefully this year".
This is all conjecture as I am afraid to call the company, I hate rejection, character flaw. |
